Dynamic Proteomic and PTMomic Characterization of Mycobacteria after Clinical Pharmaceutical Intervention

IF 3.8 2区 医学 Q2 CHEMISTRY, MEDICINAL
Jun Yin, Liming Wang, Hailong Jin, Mingya Zhang, Tian Jiang, Yunbo Kan, Tianxian Liu, Feng Su, Lei Zhao, Yi Li, Shiyang Shen, Lu Zhou, Minjia Tan, Yuanlin Song*, Lijie Tan* and Jun-Yu Xu*, 
{"title":"Dynamic Proteomic and PTMomic Characterization of Mycobacteria after Clinical Pharmaceutical Intervention","authors":"Jun Yin,&nbsp;Liming Wang,&nbsp;Hailong Jin,&nbsp;Mingya Zhang,&nbsp;Tian Jiang,&nbsp;Yunbo Kan,&nbsp;Tianxian Liu,&nbsp;Feng Su,&nbsp;Lei Zhao,&nbsp;Yi Li,&nbsp;Shiyang Shen,&nbsp;Lu Zhou,&nbsp;Minjia Tan,&nbsp;Yuanlin Song*,&nbsp;Lijie Tan* and Jun-Yu Xu*,&nbsp;","doi":"10.1021/acsinfecdis.4c00891","DOIUrl":null,"url":null,"abstract":"<p >Tuberculosis, a major global health threat, necessitates understanding the pharmacological mechanisms of current drugs to combat multidrug resistance. In addition to alterations at the proteome level, the dynamic changes occurring at various levels of post-translational modifications (PTMs) following pharmacological intervention remain unclear. In our current study, we employed a quantitative proteomic approach to systematically analyze the dynamic molecular alterations at both the proteome and PTM levels in response to clinical drugs, including ethambutol, bedaquiline, moxifloxacin, and streptomycin. Our findings revealed enriched bioprocesses beyond known functions, phosphorylation-level changes in kinases and phosphatases, and increased acetylation levels with all four drugs. Overexpression of CobB in <i>Mycobacterium smegmatis</i> significantly increased its susceptibility to ethambutol, indicating enhanced drug sensitivity. Our study provides integrated multiomics resources for understanding the dynamic molecular characteristics and drug resistance associated with clinical drug interventions and proposes novel therapeutic strategies targeting the PTM levels.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":"11 9","pages":"2398–2410"},"PeriodicalIF":3.8000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsinfecdis.4c00891","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Tuberculosis, a major global health threat, necessitates understanding the pharmacological mechanisms of current drugs to combat multidrug resistance. In addition to alterations at the proteome level, the dynamic changes occurring at various levels of post-translational modifications (PTMs) following pharmacological intervention remain unclear. In our current study, we employed a quantitative proteomic approach to systematically analyze the dynamic molecular alterations at both the proteome and PTM levels in response to clinical drugs, including ethambutol, bedaquiline, moxifloxacin, and streptomycin. Our findings revealed enriched bioprocesses beyond known functions, phosphorylation-level changes in kinases and phosphatases, and increased acetylation levels with all four drugs. Overexpression of CobB in Mycobacterium smegmatis significantly increased its susceptibility to ethambutol, indicating enhanced drug sensitivity. Our study provides integrated multiomics resources for understanding the dynamic molecular characteristics and drug resistance associated with clinical drug interventions and proposes novel therapeutic strategies targeting the PTM levels.

Abstract Image

临床药物干预后分枝杆菌的动态蛋白质组学和ptmom学特征。
结核病是一个主要的全球健康威胁,有必要了解现有药物的药理学机制,以对抗多药耐药性。除了蛋白质组水平的改变外,药物干预后不同水平的翻译后修饰(PTMs)发生的动态变化尚不清楚。在我们目前的研究中,我们采用定量蛋白质组学方法系统地分析了蛋白质组和PTM水平对临床药物(包括乙胺丁醇、贝达喹啉、莫西沙星和链霉素)的动态分子变化。我们的研究结果显示,所有四种药物都丰富了超出已知功能的生物过程,激酶和磷酸酶的磷酸化水平发生了变化,并且乙酰化水平增加。耻垢分枝杆菌中CobB的过表达显著增加了其对乙胺丁醇的敏感性,表明其药物敏感性增强。我们的研究为了解与临床药物干预相关的动态分子特征和耐药性提供了综合的多组学资源,并提出了针对PTM水平的新治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Infectious Diseases
ACS Infectious Diseases CHEMISTRY, MEDICINALINFECTIOUS DISEASES&nb-INFECTIOUS DISEASES
CiteScore
9.70
自引率
3.80%
发文量
213
期刊介绍: ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to: * Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials. * Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets. * Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance. * Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents. * Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota. * Small molecule vaccine adjuvants for infectious disease. * Viral and bacterial biochemistry and molecular biology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信